Similar articles

• Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation.

  Pratschke J, Neuhaus R, Tullius SG, Haller GW, Jonas S, Steinmueller T, Bechstein WO, Neuhaus P. Pratschke J, et al. Transplantation. 1997 Sep 27;64(6):938-40. doi: 10.1097/00007890-199709270-00029. Transplantation. 1997. PMID: 9326428
• Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation.

  Andrews WS, Sommerauer J, Conlin C, Moore P. Andrews WS, et al. Transplant Proc. 1996 Apr;28(2):897-8. Transplant Proc. 1996. PMID: 8623452 No abstract available.
• Successful conversion from cyclosporine to tacrolimus for immunosuppression.

  Sekido H, Takeda K, Morioka D, Kubota T, Togo S, Nakatani Y, Matsunami H, Lynch SV, Strong RW, Shimada H. Sekido H, et al. Transplant Proc. 2000 Nov;32(7):2120-2. doi: 10.1016/s0041-1345(00)01597-9. Transplant Proc. 2000. PMID: 11120096 No abstract available.
• Tacrolimus (FK506) is superior to cyclosporine in liver transplantation.

  Busuttil RW, Holt CD. Busuttil RW, et al. Transplant Proc. 1997 Feb-Mar;29(1-2):534-8. doi: 10.1016/s0041-1345(96)00630-6. Transplant Proc. 1997. PMID: 9123119 Review. No abstract available.
• Optimization of the use of Calcineurin inhibitors in liver transplantation.

  de Mare-Bredemeijer EL, Metselaar HJ. de Mare-Bredemeijer EL, et al. Best Pract Res Clin Gastroenterol. 2012 Feb;26(1):85-95. doi: 10.1016/j.bpg.2012.01.017. Best Pract Res Clin Gastroenterol. 2012. PMID: 22482528 Review.